/images/ppid_59c68470-image-175812003894040035.webp)
/images/ppid_59c68470-image-175807259606234170.webp)
/images/ppid_59c68470-image-175807764517146728.webp)
What is the story about?
Jusmiral Holdings is expected to sell up to 5.1% of its stake in Cohance Lifesciences
through block deals, sources with direct knowledge of the matter said on Wednesday.
The offer size is estimated at ₹1,756 crore, with a floor price of ₹900 per share, representing a 6.9% discount to the stock’s last close, the sources said.
A lock-up period of 210 days has been set for any further share sales, they added.
Cohance Lifesciences Ltd is a Hyderabad-based CDMO (Contract Development & Manufacturing Organisation) company. It offers services to international pharmaceutical, fine chemicals and biotech companies, taking projects from early-stage research through to commercial manufacturing. In May 2025, the company officially changed its name from Suven Pharmaceuticals to Cohance Lifesciences.
As of the market close on 17 September 2025, Cohance shares traded at around ₹967.70 per share, down 2.2%. This price is well off its 52-week high of ₹1,359, and has declined from earlier in the year — the stock is down about 9.7% year-to-date.
The offer size is estimated at ₹1,756 crore, with a floor price of ₹900 per share, representing a 6.9% discount to the stock’s last close, the sources said.
A lock-up period of 210 days has been set for any further share sales, they added.
Cohance Lifesciences Ltd is a Hyderabad-based CDMO (Contract Development & Manufacturing Organisation) company. It offers services to international pharmaceutical, fine chemicals and biotech companies, taking projects from early-stage research through to commercial manufacturing. In May 2025, the company officially changed its name from Suven Pharmaceuticals to Cohance Lifesciences.
As of the market close on 17 September 2025, Cohance shares traded at around ₹967.70 per share, down 2.2%. This price is well off its 52-week high of ₹1,359, and has declined from earlier in the year — the stock is down about 9.7% year-to-date.
Do you find this article useful?
/images/ppid_59c68470-image-175816753611251538.webp)
/images/ppid_59c68470-image-175817265732041367.webp)
/images/ppid_59c68470-image-175818257455811585.webp)
/images/ppid_59c68470-image-175817512609284274.webp)
/images/ppid_59c68470-image-175825760042360627.webp)
/images/ppid_59c68470-image-175819252683635258.webp)
/images/ppid_59c68470-image-175817755757468604.webp)
/images/ppid_59c68470-image-175808514513581230.webp)